Abstract: A topical formulation comprising Montelukast or a pharmaceutically acceptable salt thereof, a gelling agent and water for the treatment of atopic dermatitis.

Abstract: A depot system containing at least one antibiotic and a biodegradable poly(ester-anhydride) is provided.

Abstract: A topical formulation comprising Montelukast or a pharmaceutically acceptable salt thereof, a gelling agent and water for the treatment of atopic dermatitis.

Abstract: Embodiments of stable topical compositions for administering fenoldopam (compound (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed for immediate or continued slow release administration, over prolonged periods of time with safe minimal systemic exposure of fenoldopam (reducing the risk for lowering blood pressure). The compositions include those compositions that increase the stability and skin absorption of the drug, particularly anhydrous semi-solid compositions and creams. This is accomplished by incorporating fenoldopam in soluble or dispersed form into semi-solid compositions like ointments or anhydrous gels that are not irritative. Embodiments of methods for using the topical compositions in the treatment of dermatological disorders including psoriasis, alopecia atopic dermatitis and vitiligo are disclosed.

Abstract: The present invention relates to a pharmaceutical composition comprising granules which include an inert core coated with ferric citrate. The present invention also provides methods of manufacture thereof and methods of use thereof.

Abstract: The present invention relates to a pharmaceutical composition comprising granules which include an inert core coated with ferric citrate. The present invention also provides methods of manufacture thereof and methods of use thereof.

Abstract: A copolymer characterized by alternating or semi-alternating ester and anhydride bonds, methods for its production and use thereof, particularly as a carrier for drug delivery, are described herein.

Abstract: The present invention relates to a pharmaceutical composition comprising granules which include an inert core coated with ferric citrate. The present invention also provides methods of manufacture thereof and methods of use thereof.

Abstract: An oral modified-release formulation using Quetiapine or pharmaceutically acceptable salts thereof as an active ingredient, while avoiding the use of a gelling material. As used herein, the term “modified release” includes but is not limited to one or more of controlled release, sustained release, prolonged release and extended release.

Abstract: A method for producing granules of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, which comprises: a) mixing the angiotensin II receptor antagonist or pharmaceutically acceptable salt thereof with a melt granulating agent to form a mixture; b) elevating the temperature of the mixture to the melting point of the melt granulating agent to form a solid dispersion of the angiotensin II receptor antagonist in the melt granulating agent; and c) cooling the solid dispersion to form granules; wherein the melt granulating agent is the only granulating agent used to form the granules.